Natco Pharma Ltd. NSE: NATCOPHARM | BSE: 524816

Strong Performer, Under Radar

Download real time

884.25 -0.05 (-0.01%)

42.13% Fall from 52W High

451.5K

NSE+BSE Volume

NSE 19 Sep, 2025 3:31 PM (IST)

US FDA Classification

Natco Pharma's Hyderabad facility gets US FDA's voluntary action indicated (VAI) classification See details

Natco Pharma Ltd. share price target

Natco Pharma Ltd. has an average share price target of 1294.50. The consensus estimate represents an upside of 46.40% from the last price of 884.25. View 6 reports from 4 analysts offering long-term price targets for Natco Pharma Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	20 Sep 2025	Natco Pharma	Consensus Share Price Target	884.25	982.64	-	11.13	hold	pdf Detailed Estimates
	17 Sep 2025	Natco Pharma	Geojit BNP Paribas Target	884.25	940.00	857.25 (3.15%)	6.30	Hold	pdf post cache		Broker Report NATCO PHARMA Geojit BNP Paribas The management maintains a long-term perspective on the business, aiming to navigate potential challenges and seize growth opportunities. We anticipate a steep revenue degrowth because of lower Revlimid sales in FY27. Focus will shift on the domestic formulations business with the anticipated launches of Semaglutide, which strengthens our case for... pdf Copy Link Share on Share on Share on Share on Alert
	11 Jun 2025	Natco Pharma	Geojit BNP Paribas Target	884.25	952.00	934.10 (-5.34%)	Target met	Hold	pdf post cache		Broker Report NATCO PHARMA Geojit BNP Paribas The company unveiled its R&D product NRC-2694 for metastatic head and neck cancer, which is currently in phase 2. The management expects to gain more clarity after a year and a half. The company currently is doing patient recruitment... pdf Copy Link Share on Share on Share on Share on Alert
	30 May 2025	Natco Pharma	ICICI Securities Limited Target	884.25	890.00	883.40 (0.10%)	Target met	Hold	pdf post cache		Broker Report Near-term outlook bleak; pipeline build-up underway ICICI Securities Limited Natco’s Q4FY25 result was driven by better traction in gRevlimid and the momentum is likely to continue for next couple of quarters. pdf Copy Link Share on Share on Share on Share on Alert
	19 Mar 2025	Natco Pharma	Geojit BNP Paribas Target	884.25	887.00	825.40 (7.13%)	Target met	Hold	pdf post cache		Broker Report NATCO PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	07 Oct 2024	Natco Pharma	ICICI Direct Target	884.25	1675.00	1401.65 (-36.91%)	89.43	Buy	pdf post cache		Broker Report Natco Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	04 Oct 2024	Natco Pharma	FundsIndia	884.25	1673.00	1353.95 (-34.69%)	89.20	Buy	pdf post cache		Broker Report FundsIndia pdf Copy Link Share on Share on Share on Share on Alert
	20 Aug 2024	Natco Pharma	Geojit BNP Paribas Target	884.25	1597.00	1441.50 (-38.66%)	Target met	Accumulate	pdf post cache		Broker Report NATCO PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	13 Aug 2024	Natco Pharma	ICICI Securities Limited Target	884.25	1430.00	1475.10 (-40.05%)	Target met	Hold	pdf post cache		Broker Report Setting the stage for a strong FY25 ICICI Securities Limited Natco’s Q1FY25 beat was driven by higher sales of gRevlimid while its subsidiaries in Brazil and Canada (INR 1.8bn of sales) also did well. pdf Copy Link Share on Share on Share on Share on Alert
	30 May 2024	Natco Pharma	ICICI Direct Reco Target	884.25	1250.00	1020.30 (-13.33%)	Target met	Buy	pdf post cache		Broker Report Natco Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	27 Mar 2024	Natco Pharma	Geojit BNP Paribas Reco Target	884.25	1116.00	973.50 (-9.17%)	Target met	Accumulate	pdf post cache		Broker Report NATCO PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	21 Feb 2024	Natco Pharma	SBI Securities	884.25	977.00	1041.15 (-15.07%)	Target met	Accumulate	pdf post cache		Broker Report Pick of the Day (Short Term Delivery Call) SBI Securities Natco Pharma is a well-established player in the domestic formulations market with a significant market share in the domestic oncology segment. In oncology, it has brands catering to diseases including breast, bone, lung and ovarian cancer. pdf Copy Link Share on Share on Share on Share on Alert
	11 Aug 2023	Natco Pharma	ICICI Securities Limited Target	884.25	900.00	876.05 (0.94%)	Target met	Hold	pdf post cache		Broker Report Traction across verticals ICICI Securities Limited Natco’s Q1FY24 performance was ahead of our expectations on all fronts. gRevlimid continues to be an important growth driver though, in Q1, domestic and agrochemical biz too picked up after a long haul. Windfall from gRevlimid is invested in R&D (8-10% of sales) to build a generic pharma and agrochemical pipeline to aid growth beyond gRevlimid. pdf Copy Link Share on Share on Share on Share on Alert
	21 Jun 2023	Natco Pharma	Geojit BNP Paribas Target	884.25	765.00	623.20 (41.89%)	Target met	Buy	pdf post cache		Broker Report NATCO PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2023	Natco Pharma	ICICI Securities Limited Reco Target	884.25	650.00	618.80 (42.90%)	Target met	Hold	pdf post cache		Broker Report R&D investments picking up ICICI Securities Limited Natco Pharma’s (Natco) Q4FY23 revenue growth of 50% and margins were driven by higher sales in the export market. Company is confident of gaining further traction in the export business in the next couple of quarters. pdf Copy Link Share on Share on Share on Share on Alert
	15 Feb 2023	Natco Pharma	ICICI Direct Target	884.25	565.00	537.35 (64.56%)	Target met	Hold	pdf post cache		Broker Report Natco Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2023	Natco Pharma	ICICI Securities Limited	884.25	816.00	533.95 (65.61%)	Target met	Buy	pdf post cache		Broker Report US drives growth ICICI Securities Limited Natco Pharma’s (Natco) Q3FY23 performance was above our estimates on revenue front. Revenue grew 14% QoQ to Rs4.9bn (I-sec:4.7bn). YoY numbers are not comparable due to one-off licensing income in Q3FY22. US business saw a healthy sequential improvement driven by strong flu season sales. pdf Copy Link Share on Share on Share on Share on Alert
	05 Dec 2022	Natco Pharma	Geojit BNP Paribas Reco Target	884.25	704.00	568.05 (55.66%)	Target met	Buy	pdf post cache		Broker Report NATCO PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	17 Nov 2022	Natco Pharma	ICICI Direct Target	884.25	660.00	569.85 (55.17%)	Target met	Hold	pdf post cache		Broker Report Natco Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	14 Nov 2022	Natco Pharma	ICICI Securities Limited Target	884.25	816.00	573.40 (54.21%)	Target met	Buy	pdf post cache		Broker Report Stunted recovery mars performance ICICI Securities Limited Natco Pharma’s (Natco) Q2FY23 performance was lower than our estimates on all fronts. Revenue grew 14.6% YoY (-51.2% QoQ) to Rs4.3bn – below our expectation of Rs5.6bn. pdf Copy Link Share on Share on Share on Share on Alert
	13 Aug 2022	Natco Pharma	ICICI Direct Target	884.25	735.00	647.35 (36.60%)	Target met	Hold	pdf post cache		Broker Report Natco Pharma Limited ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners